Hemophilia A News and Research

RSS

Baxter third quarter net income increases 12% to $595 million

Baxter International Inc. today announced its financial results for the third quarter of 2010, and provided its fourth quarter and updated full-year 2010 financial outlook.

From Baxter International Inc. 21 Oct 2010

European Commission grants Ipsen's OBI-1 orphan drug status for treatment of hemophilia

Ipsen announced today that the European Commission has granted orphan drug status for OBI-1 for the treatment of hemophilia. Expected to enter pivotal clinical trials before the end of this year, OBI-1 is designed to treat individuals with hemophilia who have developed inhibitory antibodies (inhibitors) against human Factor VIII (hFVIII).

20 Oct 2010

European Commission grants orphan drug status to OBI-1 for hemophilia treatment

Inspiration Biopharmaceuticals, Inc. announced today that the European Commission has granted orphan drug status for OBI-1 for the treatment of hemophilia.

20 Oct 2010

Octapharma USA accepts applications for 25th Anniversary Grants Program

Octapharma USA is accepting applications for the Octapharma 25th Anniversary Grants Program, which supports clinical or pre-clinical research focused on human protein therapies in coagulation disorders, immune therapy, intensive care and emergency medicine. The application deadline is April 1, 2011.

15 Oct 2010

cobas TaqScreen DPX Test now available with CE Mark: Roche

Roche announced today that the cobas TaqScreen DPX Test for use on the cobas s 201 system is now available with the CE Mark. It is the first IVD test to offer complete coverage of all human genotypes of parvovirus B19 (B19V) and hepatitis A virus (HAV) in one assay.

5 Oct 2010

At six month anniversary, Obama touts benefits of health care law

Six rocky months after winning passage of the landmark health-care law, President Obama celebrated the half-year mark by holding a sunny backyard get-together in the Virginia suburbs with a sampling of Americans from across the country who he said are already benefitting.

24 Sep 2010

Annals of Internal Medicine publishes GRACE study data on HIV therapy

Data from the GRACE study will be published in the September 21st issue of the Annals of Internal Medicine. GRACE is the largest-ever study of treatment experienced adult women with HIV-1 to examine gender differences in response to HIV therapy. Sponsored by Tibotec Therapeutics Clinical Affairs, a division of Centocor Ortho Biotech Services, LLC, the GRACE study enrolled 67 percent women, demonstrating that it is possible to recruit large numbers of women into U.S.-based HIV treatment studies.

21 Sep 2010

Some health insurance changes set to take effect next week

Kaiser Health News: On Sept. 23, a number of health law provisions will go into effect, including a ban on lifetime caps on health benefits, a practice some insurance plans use to restrain costs. For one family with two children with hemophilia whose treatments cost around $250,000 a year, that's a reassuring change that means "more freedom" for the kids.

15 Sep 2010

Octapharma sponsors symposium on inhibitors in Haemophilia A

In a showing of its continued commitment to eradicating today's major complication in the treatment of haemophilia with FVIII concentrates − i.e. anti-FVIII neutralising antibodies − Octapharma AG recently sponsored a symposium, "Inhibitors in Haemophilia A: Prevention, Current Management and Personalised Therapy Perspectives", on July 13, 2010 at the World Federation of Haemophilia's (WFH's) yearly congress.

13 Sep 2010

Researchers develop new animal model for studying hemophilia A

Researchers at Yale School of Medicine have developed a new animal model for studying hemophilia A, with the goal of eventually treating people with the disorder.

3 Sep 2010

Californians recognized for contributing to plasma protein lifesaving therapies

This month, Californians are recognized for their outstanding contributions to lifesaving therapies that treat critically ill individuals and for their donations of the blood component, plasma, that makes the creation of these unique therapies possible.

3 Sep 2010

Ipsen 2010 first half revenue increases to €31.7 million

The Board of Directors of Ipsen, chaired by Jean-Luc Bélingard, met on August 30, 2010 to review the Group's results for the first half 2010, published today

31 Aug 2010

Amsterdam Molecular first half 2010 net loss in line with last year

Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, today reported its results for the first half year of 2010.

31 Aug 2010

NovoSeven RT in 8 mg vial for hemophilia A or B with inhibitors receives FDA approval

Novo Nordisk announced today that the U.S. Food and Drug Administration has approved NovoSeven® RT (Coagulation Factor VIIa [Recombinant] Room Temperature Stable) in an 8 mg vial size, making the hemophilia A or B with inhibitors treatment available in 1, 2, 5 and 8 mg vials. The 8 mg vial allows a rapid initiation and administration of this medication for those patients who need a larger dose. In addition, FDA has also approved the extension of shelf life for all vial sizes from 24 months to 36 months at room temperature (at or below 77 degrees Fahrenheit).

11 Aug 2010

New insight into protein transport mechanism can improve chemotherapy treatments

A new study conducted in the department of Biochemistry and Molecular Biology at Tel Aviv University (TAU) elucidates the way in which toxic, yet essential, copper ions enter human cells. As a chemotherapy drug presumably enters the cells in a similar manner, the results of this study pave the way for the development of improved chemotherapeutic drugs. The groundbreaking work was published in the leading American scientific journal PNAS (Proceedings of the National Academy of Sciences).

10 Aug 2010

FDA approves Pfizer's Prefilled Dual-Chamber Syringe for XYNTHA administration in hemophilia A patients

Pfizer Inc. announced today that the U.S. Food and Drug Administration has granted approval of the use of a Prefilled Dual-Chamber Syringe for administration of XYNTHA® Antihemophilic Factor (Recombinant) Plasma/Albumin-Free to hemophilia A patients. XYNTHA is a recombinant factor VIII product indicated for both the control and prevention of bleeding episodes in patients with hemophilia A (congenital factor VIII deficiency or classic hemophilia) and for surgical prophylaxis in patients with hemophilia A.

9 Aug 2010

Rush University Medical Center first to receive Octapharma grant under anniversary program

Octapharma USA today announced the first grant recipient of the Octapharma 25th Anniversary Grants Program is the Rush Hemophilia & Thrombophilia Center at Rush University Medical Center. The Octapharma grants program supports clinical or pre-clinical research focused on human protein therapies in hematology, immune therapy, intensive care and emergency medicine.

3 Aug 2010

Taiwanese hemophiliacs infected by HIV-contaminated medications petition US Supreme Court

Baum Hedlund announces that Taiwanese hemophiliacs infected by HIV-contaminated medications have petitioned the United States Supreme Court to allow their claims to proceed in California. Their suits contend that California-based defendants illegally used paid plasma donors at high risk for transmitting blood-borne diseases (i.v. drug users, prisoners, and promiscuous urban gay males) to make injected anti-hemophilia medications.

28 Jul 2010

Baxter second-quarter global sales increase 2% to $3.2 billion

Baxter International Inc. today announced its financial results for the second quarter of 2010, reporting earnings in line with the company's previously issued guidance of $0.90 to $0.93 per diluted share.

From Baxter International Inc. 22 Jul 2010

Biogen Idec second-quarter revenues increase 11% to $1.2 billion

Biogen Idec Inc., a global biotechnology leader in the discovery, development, manufacturing, and commercialization of innovative therapies, today announced its second quarter 2010 results.

20 Jul 2010